2025
Learn-As-you-GO (LAGO) trials: optimizing treatments and preventing trial failure through ongoing learning
Bing A, Spiegelman D, Nevo D, Lok J. Learn-As-you-GO (LAGO) trials: optimizing treatments and preventing trial failure through ongoing learning. Biometrics 2025, 81: ujaf061. PMID: 40407021, PMCID: PMC12099308, DOI: 10.1093/biomtc/ujaf061.Peer-Reviewed Original ResearchConceptsIntervention packageBinary outcomesIntervention effectsConditional mean modelsOptimal intervention packagesOverall intervention effectContinuous outcomesComplex intervention packagesConfidence bandsInterval estimationImplementation trialLarge-scale intervention trialsMean modelIntervention trialsHypothesis testingInterventionStandard statistical methodsOutcomesTrialsConfidenceTheory
2020
Integrating and Interpreting Findings from the Latest Treatment as Prevention Trials
Brault MA, Spiegelman D, Abdool Karim SS, Vermund SH. Integrating and Interpreting Findings from the Latest Treatment as Prevention Trials. Current HIV/AIDS Reports 2020, 17: 249-258. PMID: 32297219, PMCID: PMC7260110, DOI: 10.1007/s11904-020-00492-4.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Retroviral AgentsClinical Trials as TopicCounselingFemaleHIV InfectionsHumansIncidenceKenyaMaleMass ScreeningSouth AfricaUgandaZambia
2019
On the analysis of two‐phase designs in cluster‐correlated data settings
Rivera‐Rodriguez C, Spiegelman D, Haneuse S. On the analysis of two‐phase designs in cluster‐correlated data settings. Statistics In Medicine 2019, 38: 4611-4624. PMID: 31359448, PMCID: PMC6736737, DOI: 10.1002/sim.8321.Peer-Reviewed Original ResearchConceptsSmall-sample operating characteristicsInverse probability weighting estimatorData settingClosed-form expressionTwo-phase designStatistical efficiencyComprehensive simulation studyWeighting estimatorCovariance structureSandwich estimatorInvalid inferencesValid inferencesSimulation studyCovariate dataInverse probability weightingEstimatorNaïve methodSampling designNovel analysis approachInferenceRobust sandwich estimatorAnalysis methodAnalysis approachNational antiretroviral treatment programmeCategorical risk
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply